NPCE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

24.43M

+13.81%

-0.186

+3.11%

22.35M

-0.79%

-0.195

-7.38%

23.09M

-1.84%

-0.172

-33.67%

Estimates Revision

The market is revising Upward the revenue expectations for NeuroPace, Inc. (NPCE) for FY2025, with the revenue forecasts being adjusted by 2.17% over the past three months. During the same period, the stock price has changed by 55.05%.

Revenue Estimates for FY2025

Revise Upward

+2.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.31%

In Past 3 Month

Stock Price

Go Up

+55.05%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

18.00

High

20.00

Current: 0.000

Low

16.00

Averages

18.00

High

20.00

UBS

Buy

maintain

$18 -> $22

2025-12-16

Reason

UBS

Price Target

$18 -> $22

2025-12-16

maintain

Buy

Reason

UBS raised the firm's price target on NeuroPace to $22 from $18 and keeps a Buy rating on the shares.

JPMorgan

Rohin Patel

maintain

$18 -> $20

2025-12-10

Reason

JPMorgan

Rohin Patel

Price Target

$18 -> $20

2025-12-10

maintain

Reason

JPMorgan analyst Rohin Patel raised the firm's price target on NeuroPace to $20 from $18 and keeps an Overweight rating on the shares. The firm updated the company's model.

JPMorgan

NULL -> Overweight

maintain

$16 -> $18

2025-11-05

Reason

JPMorgan

Price Target

$16 -> $18

2025-11-05

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on NeuroPace to $18 from $16 and keeps an Overweight rating on the shares. The company reported a Q3 "beat and raise," the analyst tells investors in a research note.

H.C. Wainwright

initiated

$18

2025-05-28

Reason

H.C. Wainwright

Price Target

$18

2025-05-28

initiated

Reason

H.C. Wainwright initiated coverage of NeuroPace with a Buy rating and $18 price target. NeuroPace is a commercial-stage medical device company focused on the development and marketing of a brain-responsive neuromodulation system that can deliver personalized, real-time treatment at the seizure source for patients with drug-resistant focal epilepsy, the analyst tells investors in a research note. The firm says the cutback after the one-year data readout from the NAUTILUS study presents an attractive entry point, as the data have no impact on the sales momentum in patients with focal epilepsy.

JPMorgan

Overweight

maintain

$14 -> $16

2025-05-13

Reason

JPMorgan

Price Target

$14 -> $16

2025-05-13

maintain

Overweight

Reason

JPMorgan raised the firm's price target on NeuroPace to $16 from $14 and keeps an Overweight rating on the shares. The company reported good Q1 results ahead of the Street, with gross margin and revenue topping estimates and operating expense coming in lower, the analyst tells investors in a research note. This was another strong quarter for NeuroPace, with healthy contribution from Project Care, record new prescribers, and sustained utilization across Level 4 centers, the firm added.

Cantor Fitzgerald

Ross Osborn

Buy

Maintains

$19 → $20

2025-03-05

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$19 → $20

2025-03-05

Maintains

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Neuropace Inc (NPCE.O) is -22.27, compared to its 5-year average forward P/E of -9.02. For a more detailed relative valuation and DCF analysis to assess Neuropace Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.02

Current PE

-22.27

Overvalued PE

-2.86

Undervalued PE

-15.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.22

Current EV/EBITDA

-39.49

Overvalued EV/EBITDA

-2.41

Undervalued EV/EBITDA

-26.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.13

Current PS

5.23

Overvalued PS

6.77

Undervalued PS

1.49

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NPCE News & Events

Events Timeline

No data

News

1.0

2025-12-31Businesswire

NeuroPace to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

1.0

2025-12-31Newsfilter

NeuroPace to Present Innovative Treatment Solutions at 2026 J.P. Morgan Healthcare Conference

9.0

2025-12-17Newsfilter

NeuroPace Files PMA Supplement to Expand RNS System Indication for IGE Patients

People Also Watch

Frequently Asked Questions

What is Neuropace Inc (NPCE) stock price today?

The current price of NPCE is 16.73 USD — it has decreased -1.36 % in the last trading day.

What is Neuropace Inc (NPCE)'s business?

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.

What is the price predicton of NPCE Stock?

What is Neuropace Inc (NPCE)'s revenue for the last quarter?

Neuropace Inc revenue for the last quarter amounts to 27.35M USD, increased 29.89 % YoY.

What is Neuropace Inc (NPCE)'s earnings per share (EPS) for the last quarter?

Neuropace Inc. EPS for the last quarter amounts to -0.11 USD, decreased -42.11 % YoY.

What changes have occurred in the market's expectations for Neuropace Inc (NPCE)'s fundamentals?

How many employees does Neuropace Inc (NPCE). have?

Neuropace Inc (NPCE) has 184 emplpoyees as of January 10 2026.

What is Neuropace Inc (NPCE) market cap?

Today NPCE has the market capitalization of 557.24M USD.